Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR) a randomised, phase 3 study

被引：35
|
作者：
Motzer, Robert [1 ]
Porta, Camillo [2 ,3 ]
Alekseev, Boris [4 ]
Rha, Sun Young [5 ]
Choueiri, Toni K. [6 ]
Mendez-Vidal, Maria Jose [7 ]
Hong, Sung-Hoo [8 ]
Kapoor, Anil [9 ]
Goh, Jeffrey C. [10 ,11 ]
Eto, Masatoshi [12 ]
Bennett, Lee [13 ]
Wang, Jinyi [13 ]
Pan, Jie Janice [14 ]
Saretsky, Todd L. [15 ]
Perini, Rodolfo F. [15 ]
He, Cixin Steven
Mody, Kalgi [14 ]
Cella, David [16 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[2] Univ Bari A Moro, Interdisciplinary Dept Med, Bari, Italy
[3] Univ Pavia, Dept Biomed Sci & Human Oncol, Pavia, Italy
[4] PA Herzen Moscow Oncol Res Inst, Dept Oncourol, Moscow, Russia
[5] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[7] Univ Reina Sofia, Cordoba Hosp, Maimonides Inst Biomed Res, Cordoba, Spain
[8] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[9] McMaster Univ, Hamilton, ON, Canada
[10] South Brisbane, ICON Res, Brisbane, Qld, Australia
[11] Queensland Univ Technol, Brisbane, Qld, Australia
[12] Kyushu Univ, Fukuoka, Japan
[13] RTI Hlth Solut, Res Triangle Pk, NC USA
[14] Eisai, Nutley, NJ USA
[15] Merck & Co Inc, Kenilworth, NJ USA
[16] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 06期
关键词：
EQ-5D;
D O I：
10.1016/S1470-2045(22)00212-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Copyright (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页码：768 / 780
页数：13
相关论文
共 50 条
  • [41] Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) plus everolimus (EVE) versus sunitinib (SUN) treatment arms.
    Hutson, Thomas E.
    Choueiri, Toni K.
    Motzer, Robert J.
    Rha, Sun Young
    Alyasova, Anna
    Merchan, Jaime R.
    Gurney, Howard
    Peer, Avivit
    Takagi, Toshio
    Porta, Camillo
    Powles, Thomas
    Grunwald, Viktor
    De Giorgi, Ugo
    Vaishampayan, Ulka N.
    Schmidinger, Manuela
    Glen, Hilary
    Rodriguez-Lopez, Karla
    Xing, Dongyuan
    Dutta, Lea
    Eto, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Long-term trends in health-related quality of life in patients with metastatic renal cell carcinoma treated with cabozantinib or everolimus
    Williams, Paul
    Marteau, Florence
    Gabriel, Sylvie
    Beaumont, Jennifer
    Mangeshkar, Milan
    Baer, John
    Hankins, Matthew
    Cella, David
    QUALITY OF LIFE RESEARCH, 2017, 26 (01) : 59 - 59
  • [43] Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC).
    Lorusso, Domenica
    Colombo, Nicoletta
    Herraez, Antonio Casado
    Santin, Alessandro
    Colomba, Emeline
    Miller, David Scott
    Fujiwara, Keiichi
    Pignata, Sandro
    Baron-Hay, Sally E.
    Ray-Coquard, Isabelle Laure
    Shapira-Frommer, Ronnie
    Kim, Yong Man
    McCormack, Mary
    Bird, Steven
    Prabhu, Vimalanand S.
    Nguyen, Allison Martin
    Zhao, Qi
    Dutta, Lea
    Makker, Vicky
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] OVERALL SURVIVAL, HEALTH-RELATED QUALITY OF LIFE, AND HEALTHCARE RESOURCE USE: INDEPENDENT ANALYSES FROM CHECKMATE 025, A PHASE III STUDY OF NIVOLUMAB VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED OR METASTATIC CLEAR-CELL RENAL CELL CARCINOMA
    Taylor, F.
    Dastani, H.
    Bennett, B.
    DeRosa, M.
    Berghorn, E.
    Justin, D.
    VALUE IN HEALTH, 2016, 19 (03) : A167 - A167
  • [45] Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
    Burris, Howard A., III
    Lebrun, Fabienne
    Rugo, Hope S.
    Beck, J. Thaddeus
    Piccart, Martine
    Neven, Patrick
    Baselga, Jose
    Petrakova, Katarina
    Hortobagyi, Gabriel N.
    Komorowski, Anna
    Chouinard, Edmond
    Young, Robyn
    Gnant, Michael
    Pritchard, Kathleen I.
    Bennett, Lee
    Ricci, Jean-Francois
    Bauly, Hounayda
    Taran, Tetiana
    Sahmoud, Tarek
    Noguchi, Shinzaburo
    CANCER, 2013, 119 (10) : 1908 - 1915
  • [46] Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) a randomised, double-blind, phase 3 trial
    Llovet, Josep M.
    Kudo, Masatoshi
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Masi, Gianluca
    Kwiatkowski, Mariusz
    Lim, Ho Yeong
    Kim, Jee Hyun
    Breder, Valeriy
    Kumada, Hiromitsu
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Wang, Anran
    Mody, Kalgi
    Dutcus, Corina
    Dubrovsky, Leonid
    Siegel, Abby B.
    Finn, Richard S.
    LANCET ONCOLOGY, 2023, 24 (12): : 1399 - 1410
  • [47] Risk of health-related quality of life and metabolic events and pulmonary toxicities in patients with advanced renal cell carcinoma treated with everolimus: A meta-analysis of phase 3 randomized controlled trials
    Yendala, Rachana
    Thein, Kyaw Zin
    Swarup, Sriman
    Sultan, Anita
    D'Cunha, Nicholas C.
    Awasthi, Sanjay
    Tijani, Lukman
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Characteristics and management of major adverse events in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab based on results from the CLEAR trial
    Motzer, R.
    George, S.
    Merchan, J. R.
    Hutson, T. E.
    Song, X.
    Perini, R. F.
    Xie, R.
    Bapat, U.
    Puente, J.
    ONKOUROLOGIYA, 2023, 19 (02): : 29 - 40
  • [49] A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinoma
    Hutson, Thomas
    Xing, Dongyuan
    Dutcus, Corina
    Baig, Mahadi
    Fishman, Mayer
    BJU INTERNATIONAL, 2016, 118 : 14 - 15
  • [50] Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
    Mansoor, Wasat
    Joo, Seongjung
    Norquist, Josephine M.
    Kato, Ken
    Sun, Jong-Mu
    Shah, Manish A.
    Enzinger, Peter
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chol
    Sunpaweravong, Patrapim
    Maqueda, Maria Alsina
    Goekkurt, Eray
    Suryawanshi, Shailaja
    Shah, Sukrut
    Shen, Lin
    ONCOLOGIST, 2024, 29 (10): : e1324 - e1335
12345